Free Trial
NASDAQ:GOSS

Gossamer Bio (GOSS) Stock Price, News & Analysis

$0.93
+0.02 (+2.20%)
(As of 04:16 PM ET)
Today's Range
$0.90
$0.97
50-Day Range
$0.79
$1.25
52-Week Range
$0.45
$1.60
Volume
532,376 shs
Average Volume
1.59 million shs
Market Capitalization
$210.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.20

Gossamer Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
892.1% Upside
$9.20 Price Target
Short Interest
Healthy
4.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.77mentions of Gossamer Bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$249,240 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.33) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.38 out of 5 stars

Medical Sector

102nd out of 899 stocks

Pharmaceutical Preparations Industry

36th out of 420 stocks

GOSS stock logo

About Gossamer Bio Stock (NASDAQ:GOSS)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

GOSS Stock Price History

GOSS Stock News Headlines

Gossamer Bio (NASDAQ:GOSS) Earns "Buy" Rating from HC Wainwright
Biden’s Capital Gains Tax to Devastate Savings!
Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.
What It Takes to Perform Brain Surgery
Barclays Reaffirms Their Hold Rating on Gossamer Bio (GOSS)
Biden’s Capital Gains Tax to Devastate Savings!
Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.
GOSS Gossamer Bio, Inc.
See More Headlines
Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/12/2024
Today
9/09/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.20
High Stock Price Target
$15.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+855.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-179,820,000.00
Pretax Margin
-79.73%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.28 per share

Miscellaneous

Free Float
214,908,000
Market Cap
$217.72 million
Optionable
Optionable
Beta
1.95
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Faheem Hasnain (Age 66)
    Co-Founder, CEO, President & Chairman
    Comp: $910.26k
  • Mr. Bryan GiraudoMr. Bryan Giraudo (Age 49)
    COO & CFO
    Comp: $708.09k
  • Mr. Robert P. Smith (Age 55)
    Chief Commercial Officer
    Comp: $135.79k
  • Mr. Christian Waage (Age 57)
    Executive Vice President of Technical Operations & Administration
    Comp: $583.16k
  • Mr. Jeff Boerneke
    General Counsel & Secretary
  • Ms. Deanna Weber
    Senior Vice President of Human Resources
  • Dr. Richard Aranda M.D. (Age 63)
    Chief Medical Officer
    Comp: $625.24k
  • Mr. Mario Orlando
    Senior Vice President of Commercial New Product Planning
  • Ms. Caryn L. Peterson (Age 65)
    Executive Vice President of Regulatory Affairs
  • Mr. Matt Cravets
    Senior Vice President of Biometrics

GOSS Stock Analysis - Frequently Asked Questions

How have GOSS shares performed this year?

Gossamer Bio's stock was trading at $0.9125 at the beginning of the year. Since then, GOSS shares have increased by 1.6% and is now trading at $0.9273.
View the best growth stocks for 2024 here
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) announced its earnings results on Monday, August, 12th. The company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.23 by $0.01. The company had revenue of $95.84 million for the quarter, compared to analysts' expectations of $160 million.

When did Gossamer Bio IPO?

Gossamer Bio (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

Who are Gossamer Bio's major shareholders?

Top institutional shareholders of Gossamer Bio include NEA Management Company LLC (8.00%), Millennium Management LLC (2.47%), Acadian Asset Management LLC (1.59%) and Marshall Wace LLP (1.47%). Insiders that own company stock include Faheem Hasnain, Richard Aranda, Bryan Giraudo, Laura Carter and Caryn Peterson.
View institutional ownership trends
.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Gossamer Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC) and NVIDIA (NVDA).

This page (NASDAQ:GOSS) was last updated on 9/9/2024 by MarketBeat.com Staff

From Our Partners